Prior to co-founding Medicxi Ventures, Francesco was with Index Ventures for 18 years, having joined the firm in 1997 to launch its life sciences practice. While at Index life sciences, he spearheaded the creation and adoption of the asset-centric investment strategy and led the growth of the firm. At Medicxi he also oversees the firm’s operations.
Francesco’s investments include CellZome (acquired by GlaxoSmithKline), Egalet (Nasdaq: EGLT), GenMab (Copenhagen: GEN.CO), GenSight Biologics, Micromet (acquired by Amgen), Minerva Neurosciences (Nasdaq: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, Nasdaq: AFFX), Profibrix (acquired by The Medicines Company), Versartis (Nasdaq: VSAR) and several others.
Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral scientist at the Whitehead Institute at MIT. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva.
|Oct, 2013||Versartis||$20M / Series D||Index Ventures|
|Jul, 2013||Versartis||$12.5M / Series C||Index Ventures|
|Jul, 2013||Sequenta||$20M / Series C||Index Ventures|
|Jan, 2013||Versartis||$25M / Series C||Index Ventures|
|Jan, 2012||Sequenta||$8.46M / Venture||Index Ventures|
|Feb, 2011||Versartis||$21M / Series B||Index Ventures|
|Dec, 2010||Sequenta||$13M / Series B||Index Ventures|
|Jun, 2009||Versartis||$11M / Series A (Lead)||Index Ventures|
|Feb 2, 2016||Med City News - Morning Read: Iowa caucus results show single payer lives (at least in Bernie Sanders’ mind)|
|Feb 2, 2016||PRNewswire UK All - Medicxi Ventures, Formerly Index Ventures Life Sciences, Launches as an Independent Venture Capital Firm and Announces Closing of a €210m Fund including GSK and Johnson & Johnson Innovation|
|Feb 2, 2016||StrictlyVC - StrictlyVC: February 2, 2016|
|Feb 2, 2016||Channel News Asia - Tech - GSK and J&J back US$1 billion biotech spin-off from Index Ventures|
|Feb 2, 2016||Startup Ticker (Switzerland) - Medicxi Ventures closes a €210m Fund including GSK and Johnson & Johnson Innovation|
|Dec 15, 2015||Xconomy - London Notebook: Conversations Inside The Biomedical Golden Triangle|
|Mar 18, 2015||Fierce Biotech - J&J stays mum about cash, but biotech buyout is a landmark win for Index fund|
|Mar 20, 2012||TechCrunch - Index Launches Its First Life Sciences Fund: $200M And Partnering With Glaxo and Johnson & Johnson|